Safety and Tolerability of Ribavirin (Ro 20-9963) in Combination With Peginterferon Alfa in Patients With Chronic Hepatitis C.

Trial Profile

Safety and Tolerability of Ribavirin (Ro 20-9963) in Combination With Peginterferon Alfa in Patients With Chronic Hepatitis C.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 May 2013

At a glance

  • Drugs Peginterferon alfa (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 18 Oct 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 18 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Planned number of patients changed from 1803 to 2500 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top